Core Scientific (CORZ) Valuation Check As US$1b J.P. Morgan Facility Backs AI Colocation Pivot

Core Scientific (CORZ) expanded its credit facility with J.P. Morgan to US$1b, giving the company fresh capital to fund data center upgrades and energy projects tied to its shift toward AI focused colocation.

See our latest analysis for Core Scientific.

The expanded J.P. Morgan facility lands at a time when Core Scientific’s short term momentum is picking up, with a 7 day share price return of 12.46% and year to date share price return of 14.57%. The 1 year total shareholder return of roughly 1.6x signals strong longer term gains that investors are now reassessing in light of the pivot toward AI focused colocation.

If AI infrastructure is on your radar, this is a good moment to scan the wider opportunity set and see which other names are moving through the 36 AI infrastructure stocks

With the shares up strongly over 1 year and the last close at US$18.32 versus an average analyst target of about US$26.36, the key question is whether Core Scientific still trades at a discount or if the AI pivot is already fully priced in.

Most Popular Narrative: 30.6% Undervalued

With Core Scientific last closing at $18.32 versus a narrative fair value of about $26.40, the current pricing sits well below what the most followed thesis implies.

Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12 year term, significantly boosting future revenue compared to their current levels. The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise.

Read the complete narrative.

Want to see what kind of revenue ramp and margin shift this thesis is leaning on? The fair value hinges on aggressive top line growth and a very different earnings profile. Curious how those assumptions stack up against the current loss making base and heavy capital needs?

Result: Fair Value of $26.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are clear pressure points, including reliance on CoreWeave for a large revenue stream and the company’s recent US$265m quarterly loss following its Chapter 11 restructuring.

Find out about the key risks to this Core Scientific narrative.

Another View: Valuation Multiples Paint a Tougher Picture

The narrative fair value of about $26.40 suggests upside from the current $18.32 share price, but the current P/S of 18.1x tells a very different story. That multiple sits well above the US Software industry at 3.3x, the peer average at 3.4x, and even the fair ratio of 5.3x. This points to meaningful valuation risk if sentiment cools.

For investors who prefer simple comparables over long term narratives, this kind of gap raises a practical question: is the market already paying well ahead of where the sales multiple could realistically settle once the AI colocation story matures?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and risk so far? Review the numbers in more detail, then weigh the upside and downside for yourself with the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that better fit your goals, risk comfort, and income needs. Consider broadening your watchlist thoughtfully.

• Target potential mispricings by scanning for companies that combine quality with attractive valuations through the 57 high quality undervalued stocks
• Strengthen your income stream by reviewing businesses that offer resilient payouts and higher yields using the 11 dividend fortresses
• Prioritize resilience by focusing on companies with healthier balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (41 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com